Novo Nordisk walked away from a $10 billion biotech deal — and investors aren’t sure if that’s smart or scary
A failed acquisition bid, U.S. pricing deals, and boardroom drama pose challenges for the Danish pharma giant.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.